Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent <scp>HCV</scp> genotype 1 infection

Martinello, Marianne; Bhagani, Sanjay; Gane, Edward; Orkin, Chloe; Cooke, Graham; Dore, Gregory J.; Petoumenos, Kathy; Applegate, Tanya; Tu, Elise; Marks, Philippa; Pagani, Nicole; Grebely, Jason; Nelson, Mark; Matthews, Gail V.

doi:10.1111/jvh.12917

Cited by 27 publications

(19 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…362 The combination of ritonavir-boosted paritaprevir, ombitasvir and dasabuvir administered for 8 weeks yielded a 97% (29/30; 1 non-virological failure) SVR rate in patients with recently acquired hepatitis C in the TARGET-3D study. 363 Finally, 6 weeks of treatment with glecaprevir/pibrentasvir yielded a 90% SVR12 rate (27/30; 1 virological failure) in patients with recently acquired hepatitis C. 364 In a multicentre international, open-label trial, patients with recently acquired hepatitis C were randomised into 2 groups to receive either 6 or 12 weeks of the fixed-dose combination of sofosbuvir and velpatasvir. Interim analysis results were presented from 127 of the planned 250 inclusions.…”

Section: Treatment Of Recently Acquired Hepatitis Cmentioning

confidence: 99%

EASL recommendations on treatment of hepatitis C: Final update of the series☆

Pawlotsky¹,

Negro²,

Aghemo³

et al. 2020

Journal of Hepatology

805

632

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Clinical care for patients with HCV-related liver disease has advanced considerably thanks to an enhanced understanding of the pathophysiology of the disease, as well as developments in diagnostic procedures and improvements in therapy and prevention. These therapies make it possible to eliminate hepatitis C as a major public health threat, as per the World Health Organization target, although the timeline and feasibility vary from region to region. These European Association for the Study of the Liver recommendations on treatment of hepatitis C describe the optimal management of patients with recently acquired and chronic HCV infections in 2020 and onwards.

show abstract

Section: Treatment Of Recently Acquired Hepatitis Cmentioning

confidence: 99%

EASL recommendations on treatment of hepatitis C: Final update of the series☆

Pawlotsky¹,

Negro²,

Aghemo³

et al. 2020

Journal of Hepatology

805

632

View full text Add to dashboard Cite

show abstract

“…17 Another study reported comparable SVR12 results (97%; 29/30) following eight weeks of treatment with 3D AE RBV in HIV-positive patients with recent HCV infection. 18 Nevertheless, the optimal duration and outcome of IFN-free therapy in HIV/AHC remain unclear, since all conducted studies had heterogeneous inclusion criteria and suffered from small sample size. 19 Notably, previous data suggested that even a short duration of HCV infection might induce significant liver fibrosis and substantial liver damage in HIV-positive MSM, 20 underlining the urge to initiate treatment early.…”

Section: Introductionmentioning

confidence: 99%

High efficacy of interferon‐free therapy for acute hepatitis C in HIV‐positive patients

et al. 2019

View full text Add to dashboard Cite

Background The treatment of acute hepatitis C (AHC) with direct-acting antiviral agents (DAAs) is considered a cornerstone of hepatitis C virus (HCV) elimination strategies, especially in human immunodeficiency virus (HIV)-infected individuals at high risk of onward transmission. Objective Optimal treatment regimens and duration for AHC in HIV-coinfected patients remain to be established. Thus, we aimed to evaluate the efficacy and safety of DAA treatment regimens in the setting of AHC. Methods All HIV-positive patients with a diagnosis of AHC according to the European AIDS Treatment Network (NEAT) consensus attending our clinic after 2014 were included. DAA treatment regimens and duration were based on current recommendations for chronic hepatitis C (CHC) at treatment initiation. Results Thirty-eight HIV/AHC patients (median age 42.0 years), mostly men who have sex with men (92%), were started on interferon-free regimens. HCV-genotype (GT) was predominately GT-1a (65%). The following DAA regimens were prescribed: ombitasvir/paritaprevir/ritonavir/dasabuvir (42%; 16/38), glecaprevir/pibrentasvir (29%; 11/38), sofosbuvir/ledipasvir (13%; 5/38), ombitasvir/paritaprevir/ritonavir (5%; 2/38), grazoprevir/elbasvir (5%; 2/38) and sofosbuvir/velpatasvir (5%; 2/38). All HIV/AHC patients achieved sustained virologic response 12 weeks after end of treatment (SVR12) (100%; 38/38). DAA-related adverse events were rare. Conclusion Interferon-free DAA regimens (including 34% pan-genotypic regimens) yielded 100% SVR12 in HIV/AHC individuals if treatment durations similar to CHC are applied.

show abstract

“…The median time between diagnosis and treatment (15 weeks) was a little shorter than in our study, but the median VL (6.2 log 10 IU/mL) was higher and the median ALT (133 U/L) lower than in our study. Martinello et al [ 23 ] treated with 8 weeks of the no longer widely used regimen of paritaprevir/ritonavir/ombitasvir, dasabuvir, and ribavirin and cured all 23 HIV-infected participants. The median time between diagnosis and treatment (23 weeks) was the longest among these studies, although despite this longer time to treatment, the median HCV VL (5.7 log 10 IU/mL) and ALT level (~150 U/L) were about intermediate between the Naggie et al study and ours.…”

Section: Discussionmentioning

confidence: 99%

Ledipasvir and Sofosbuvir in the Treatment of Early Hepatitis C Virus Infection in HIV-Infected Men

Palaniswami¹,

Sayed²,

Asriel³

et al. 2018

Open Forum Infectious Diseases

View full text Add to dashboard Cite

BackgroundTreatment of HIV-infected men during early hepatitis C virus (HCV) infection with interferon results in a higher cure rate with a shorter duration of treatment than during chronic HCV infection. We recently demonstrated that this phenomenon applied to interferon-free treatment as well, curing most participants with short-course sofosbuvir and ribavirin. Due to the significantly higher potency of the ledipasvir/sofosbuvir (LDV/SOF) combination, we hypothesized that we would be more successful in curing early HCV infections using a shorter course of LDV/SOF than that used for treating chronic HCV infections.MethodsWe performed a prospective, open-label, consecutive case series study of 8 weeks of LDV/SOF in HIV-infected men with early genotype 1 HCV infection. The primary end point was aviremia at least 12 weeks after completion of treatment.ResultsWe treated 25 HIV-infected men with early sexually acquired HCV infection with 8 weeks of LDV/SOF, and all 25 (100%) were cured. Twelve (48%) reported sexualized drug use with methamphetamine.ConclusionsEight weeks of LDV/SOF cured all 25 HIV-infected men with early HCV infection, including those who were actively using drugs. Based on these results, we recommend treatment of newly HCV-infected men during early infection, regardless of drug use, to both take advantage of this 8-week treatment and to decrease further HCV transmission among this group of men.

show abstract

Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection

Cited by 27 publications

References 22 publications

EASL recommendations on treatment of hepatitis C: Final update of the series☆

EASL recommendations on treatment of hepatitis C: Final update of the series☆

High efficacy of interferon‐free therapy for acute hepatitis C in HIV‐positive patients

Ledipasvir and Sofosbuvir in the Treatment of Early Hepatitis C Virus Infection in HIV-Infected Men

Contact Info

Product

Resources

About